Rosetta Genomics Completes Private Placement Tranche

Feb 23, 2017

NEW YORK (GenomeWeb) – Rosetta Genomics announced today that it has completed the second tranche of a previously announced $5 million placement of stock and convertible debentures.

In the new tranche, the firm sold newly registered convertible debentures, which can be converted into about 2.6 million ordinary shares, for gross proceeds of $1.3 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Menu

Rosetta Genomics Completes Private Placement Tranche

To read the full story....

Breaking News

FDA Approves Qiagen's PIK3CA Test as Companion Test for Novartis Breast Cancer Drug

Local Coverage Determinations Roundup: Natera, Guardant Health, Transplant Genomics, and More

In Brief This Week: Invivoscribe, Todos Medical, Personalis, and More

FDA Approves CD Diagnostics' Test for Prosthetic Joint Infections

FDA Clears InBios International Zika Antibody Test

Beckman Coulter Life Sciences Recalls Hematology Analyzers Due to Risk of Inaccurate Results

Featured White Papers

Lowering RNA-seq Costs via Enzymatic rRNA Depletion with Custom, Species-specific Probes

Clinical Genomics of NTRK Fusion Detection in Cancer

Genome-Wide NIPT for Rare Chromosomal Conditions: Technical, Biological, and Clinical Considerations

Error-Corrected Sequencing to Detect Measurable Residual Disease in Post-Transplant MDS Cases

What's Popular?

FDA Approves Qiagen's PIK3CA Test as Companion Test for Novartis Breast Cancer Drug

Roche Obtains FDA Clearance for Sexually Transmitted Disease Test

FDA Clears Cepheid, Hologic CT/NG Assays for Extragenital Testing

Local Coverage Determinations Roundup: Natera, Guardant Health, Transplant Genomics, and More

Startup Novel Microdevices Developing Rapid Point-of-Care MDx System for STIs

Sponsorships